One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Farewell from the CKJ Editor-in-Chief: key kidney topics from 2014 to 2021
Alberto Ortiz, Caroline Vinck
doi : 10.1093/ckj/sfac023
Clinical Kidney Journal, Volume 15, Issue 4, April 2022, Pages 593–602
The year 2021 was the last full year of Alberto Ortiz’s editorship at Clinical Kidney Journal (CKJ). On May 2022, Maria José Soler will start her term as the Editor-in-Chief. Over these years, CKJ obtained its first journal impact factor and has consolidated its position among the top journals in the field, consistently ranking among the top 25% (first quartile) journals in Urology and Nephrology. The 2020 journal impact factor rose to 4.45, becoming the top open access journal in Nephrology and the ninth ranked Nephrology journal overall. We now review the recent history of the journal and the most highly cited topics which include the epidemiology of kidney disease, chronic kidney disease topics, such as the assessment and treatment of chronic kidney disease, onconephrology, cardionephrology, glomerular disease, transplantation and coronavirus disease 2019 (COVID-19).
Kidney health for all: bridging the gap in kidney health education and literacy
Robyn G Langham, Kamyar Kalantar-Zadeh, Ann Bonner, Alessandro Balducci, Li-Li Hsiao, Latha A Kumaraswami, Paul Laffin, Vassilios Liakopoulos, Gamal Saadi, Ekamol Tantisattamo, Ifeoma Ulasi, Siu-Fai Lui, The World Kidney Day Joint Steering Committee
doi : 10.1093/ckj/sfac040
Clinical Kidney Journal, Volume 15, Issue 4, April 2022, Pages 603–610
The high burden of kidney disease, global disparities in kidney care and poor outcomes of kidney failure bring a concomitant growing burden to persons affected, their families and caregivers and the community at large. Health literacy is the degree to which persons and organizations have or equitably enable individuals to have the ability to find, understand and use information and services to make informed health-related decisions and actions for themselves and others. Rather than viewing health literacy as a patient deficit, improving health literacy largely rests with healthcare providers communicating and educating effectively in codesigned partnership with those with kidney disease. For kidney policymakers, health literacy provides the imperative to shift organizations to a culture that places the person at the center of healthcare. The growing capability of and access to technology provides new opportunities to enhance education and awareness of kidney disease for all stakeholders. Advances in telecommunication, including social media platforms, can be leveraged to enhance persons’ and providers’ education. The World Kidney Day declares 2022 as the year of ‘Kidney Health for All’ to promote global teamwork in advancing strategies in bridging the gap in kidney health education and literacy. Kidney organizations should work toward shifting the patient-deficit health literacy narrative to that of being the responsibility of healthcare providers and health policymakers. By engaging in and supporting kidney health–centered policymaking, community health planning and health literacy approaches for all, the kidney communities strive to prevent kidney diseases and enable living well with kidney disease.
Calciphylaxis after kidney transplantation: a rare but life-threatening disorder
Manuel Alfredo Podestà , Paola Ciceri, Andrea Galassi, Mario Cozzolino
doi : 10.1093/ckj/sfab247
Clinical Kidney Journal, Volume 15, Issue 4, April 2022, Pages 611–614
Calciphylaxis is a rare disorder characterized by vascular calcification and thrombosis of the subcutaneous microcirculation, leading to painful necrotic skin lesions and bearing a dreadfully high mortality rate. This syndrome is frequently also termed uraemic calcific arteriolopathy, since most cases are observed in patients with kidney failure. However, it is increasingly clear that calciphylaxis may also affect patients with normal or only slightly impaired renal function, including kidney transplant recipients. A precise definition of the characteristics and risk factors of calciphylaxis developing after kidney transplantation has been hindered by the extreme rarity of this condition, which also hampered the development of effective therapeutic strategies. In the present issue of CKJ, Guillén and colleagues report the largest case series of calciphylaxis in kidney transplant recipients to date, outlining several features that are apparently specific to this population. In this editorial, we briefly present the epidemiology and pathogenesis of calciphylaxis in different patient populations and discuss recent findings for its therapeutic management.
Ethical challenges in managing unvaccinated patients receiving chronic in-centre haemodialysis
Gaetano Alfano, Francesco Fontana, Niccolò Morisi, Giacomo Mori, Gianni Cappelli, Riccardo Magistroni, Gabriele Donati
doi : 10.1093/ckj/sfab276
Clinical Kidney Journal, Volume 15, Issue 4, April 2022, Pages 615–617
Insufficient vaccine coverage and dominance of the more transmissible severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants are the leading causes of the continued spread of coronavirus disease 2019 (COVID-19) worldwide. To curb the surge in infections, COVID-19 vaccination has been advocated as a priority measure, especially for frail populations and people at high risk of exposure. Patients on in-centre maintenance haemodialysis (HD) embody both conditions. They are at high risk of severe COVID-19 consequences due to their advanced age and weakened immune system and carry an increased risk of SARS-CoV-2 transmission within shared dialysis rooms and public vehicles. Vaccination of the entire HD population is therefore the most effective strategy to protect patients from the dire consequences of COVID-19. Unfortunately, a minority of patients still express COVID-19 vaccine hesitancy. The management of this group of patients, who have the full right to HD treatment, poses demanding problems from a patient safety perspective. The placement of unvaccinated patients within the dialysis room and the protection of all vaccinated patients are some of the most urgent problems the nephrologist faces during the COVID-19 pandemic. In light of these COVID-19-driven changes, an ethical reflection on the management of unvaccinated patients appears crucial to act responsibly and contribute to the health promotion of dialysis patients.
Cardiovascular disease and ANCA-associated vasculitis: are we missing a beat?
Lauren Floyd, Adam D Morris, Alexander Woywodt, Ajay Dhaygude
doi : 10.1093/ckj/sfac009
Clinical Kidney Journal, Volume 15, Issue 4, April 2022, Pages 618–623
The association between cardiovascular (CV) disease and anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is well documented. The recent work by Massicotte-Azarniouch et al. confirms the risk and adds to the existing evidence by describing the highest risk in the first 3 months after diagnosis. In this review, we aim to put their findings into perspective and formulate implications for the care of AAV patients. We discuss mechanisms for increased CV disease in AAV, including the impact of traditional risk factors and disease-related risks such as renal impairment and anti-myeloperoxidase (MPO) ANCA serotype. We also provide a brief primer on the impact of inflammatory-driven endothelial dysfunction and platelet activation on accelerated atherosclerosis in AAV patients. These features alongside the impact of disease activity and systemic inflammation provide potential explanations to why the incidence of CV events is highest in the first 3 months from diagnosis. We suggest future avenues of research, provide some suggestions to address and treat CV risk based on current evidence, and highlight the importance of addressing this topic early on. Addressing modifiable risk factors, dialogue with patients, patient information and a structured approach overall will be key to improve CV outcomes in AAV.
Albumin is an interface between blood plasma and cell membrane, and not just a sponge
Jens van de Wouw, Jaap A Joles
doi : 10.1093/ckj/sfab194
Clinical Kidney Journal, Volume 15, Issue 4, April 2022, Pages 624–634
Albumin is the most abundant protein in blood plasma and acts as a carrier for many circulating molecules. Hypoalbuminaemia, mostly caused by either renal or liver disease or malnutrition, can perturb vascular homeostasis and is involved in the development of multiple diseases. Here we review four functions of albumin and the consequences of hypoalbuminaemia on vascular homeostasis. (i) Albumin is the main determinant of plasma colloid osmotic pressure. Hypoalbuminaemia was therefore thought to be the main mechanism for oedema in nephrotic syndrome (NS), however, experimental studies showed that intrarenal mechanisms rather than hypoalbuminaemia determine formation and, in particular, maintenance of oedema. (ii) Albumin functions as an interface between lysophosphatidylcholine (LPC) and circulating factors (lipoproteins and erythrocytes) and the endothelium. Consequently, hypoalbuminaemia results in higher LPC levels in lipoproteins and erythrocyte membrane, thereby increasing atherosclerotic properties of low-density lipoprotein and blood viscosity, respectively. Furthermore, albumin dose-dependently restores LPC-induced inhibition of vasodilation. (iii) Hypoalbuminaemia impacts on vascular nitric oxide (NO) signalling by directly increasing NO production in endothelial cells, leading to reduced NO sensitivity of vascular smooth muscle cells. (iv) Lastly, albumin binds free fatty acids (FFAs). FFAs can induce vascular smooth muscle cell apoptosis, uncouple endothelial NO synthase and decrease endothelium-dependent vasodilation. Unbound FFAs can increase the formation of reactive oxygen species by mitochondrial uncoupling in multiple cell types and induce hypertriglyceridemia in NS. In conclusion, albumin acts as an interface in the circulation and hypoalbuminaemia impairs multiple aspects of vascular function that may underlie the association of hypoalbuminaemia with adverse outcomes. However, hypoalbuminaemia is not a key to oedema in NS. These insights have therapeutic implications.
Robot-assisted kidney transplantation: an update
Harry V M Spiers, Videha Sharma, Alexander Woywodt, Rajesh Sivaprakasam, Titus Augustine
doi : 10.1093/ckj/sfab214
Clinical Kidney Journal, Volume 15, Issue 4, April 2022, Pages 635–643
Renal transplantation has become the gold-standard treatment for the majority of patients with established renal failure. Recent decades have seen significant progress in immunosuppressive therapies and advances in post-transplant management of recipients, resulting in improved graft and patient outcomes. However, the open technique of allograft implantation has stood the test of time, remaining largely unchanged. In a world where major advances in surgery have been facilitated by innovations in the fields of biotechnology and medical instrumentation, minimally invasive options have been introduced for the recipient undergoing kidney transplantation. In this review we present the evolution of minimally invasive kidney transplantation, with a specific focus on robot-assisted kidney transplant and the benefits it offers to specific patient groups. We also discuss the ethical concerns that must be addressed by transplant teams considering developing or referring to robotic programs.
Risk for subsequent hypertension and cardiovascular disease after living kidney donation: is it clinically relevant?
Charles J Ferro, Jonathan N Townend
doi : 10.1093/ckj/sfab271
Clinical Kidney Journal, Volume 15, Issue 4, April 2022, Pages 644–656
The first successful live donor kidney transplant was performed in 1954. Receiving a kidney transplant from a live kidney donor remains the best option for increasing both life expectancy and quality of life in patients with end-stage kidney disease. However, ever since 1954, there have been multiple questions raised on the ethics of live kidney donation in terms of negative impacts on donor life expectancy. Given the close relationship between reduced kidney function in patients with chronic kidney disease (CKD) and hypertension, cardiovascular disease and cardiovascular mortality, information on the impact of kidney donation on these is particularly relevant. In this article, we review the existing evidence, focusing on the more recent studies on the impact of kidney donation on all-cause mortality, cardiovascular mortality, cardiovascular disease and hypertension, as well as markers of cardiovascular damage including arterial stiffness and uraemic cardiomyopathy. We also discuss the similarities and differences between the pathological reduction in renal function that occurs in CKD, and the reduction in renal function that occurs because of a donor nephrectomy. Kidney donors perform an altruistic act that benefits individual patients as well as the wider society. They deserve to have high-quality evidence on which to make informed decisions.
Precision medicine for the treatment of glomerulonephritis: a bold goal but not yet a transformative achievement
Richard J Glassock
doi : 10.1093/ckj/sfab270
Clinical Kidney Journal, Volume 15, Issue 4, April 2022, Pages 657–662
The revolution in our ability to recognize the alterations in fundamental biology brought about by disease has fostered a renewed interest in precision or personalized medicine (‘the right treatment, or diagnostic test, for the right patient at the right time’). This nascent field has been led by oncology, immunohematology and infectious disease, but nephrology is catching up and quickly. Specific forms of glomerulonephritis (GN) thought to represent specific ‘diseases’ have been ‘downgraded’ to ‘patterns of injury’. New entities have emerged through the application of sophisticated molecular technologies, often embraced by the term ‘multi-omics’. Kidney biopsies are now interpreted by next-generation imaging and machine learning. Many opportunities are manifest that will translate these remarkable developments into novel safe and effective treatment regimens for specific pathogenic pathways evoking GN and its progression to kidney failure. A few successes embolden a positive look to the future. A sustained and highly collaborative engagement with this new paradigm will be required for this field, full of hope and high expectations, to realize its goal of transforming glomerular therapeutics from one size fits all (or many) to a true individualized management principle.
Development of calciphylaxis in kidney transplant recipients with a functioning graft
Elena Guillén-Olmos, Jose Vicente Torregrosa, Adriana Garcia-Herrera, Sergi Ganau, Fritz Diekmann, David Cucchiari
doi : 10.1093/ckj/sfab205
Clinical Kidney Journal, Volume 15, Issue 4, April 2022, Pages 663–671
Calciphylaxis is not uniquely observed in uraemic patients, as some cases have also been reported in patients with normal renal function or moderate chronic kidney disease (CKD), in association with severe vasculopathy or systemic inflammation. A particular subset worthy of studying is represented by those patients who develop calciphylaxis after kidney transplantation (KT).
Randomized comparison of three high-flux dialyzers during high-volume online hemodiafiltration—the comPERFORM study
Götz Ehlerding, Wolfgang Ries, Manuela Kempkes-Koch, Ekkehard Ziegler, Ansgar Erlenkötter, Adam M Zawada, James P Kennedy, Bertram Ottillinger, Manuela Stauss-Grabo, Thomas Lang
doi : 10.1093/ckj/sfab196
Clinical Kidney Journal, Volume 15, Issue 4, April 2022, Pages 672–680
Dialyzers should be designed to efficiently eliminate uraemic toxins during dialysis treatment, given that the accumulation of small and middle molecular weight uraemic solutes is associated with increased mortality risk of patients with end-stage renal disease. In the present study we investigated the novel FX CorAL dialyzer with a modified membrane surface for performance during online hemodiafiltration (HDF) in a clinical setting.
Association of anti-neutrophil cytoplasmic antibody-associated vasculitis and cardiovascular events: a population-based cohort study
David Massicotte-Azarniouch, William Petrcich, Michael Walsh, Mark Canney, Gregory L Hundemer, Nataliya Milman, Michelle A Hladunewich, Todd Fairhead, Manish M Sood
doi : 10.1093/ckj/sfab229
Clinical Kidney Journal, Volume 15, Issue 4, April 2022, Pages 681–692
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is implicated in elevating the risk for cardiovascular (CV) disease; whether the elevated risk applies to all types of CV diseases or specific types is unclear. This study examined the association of AAV and adverse CV outcomes compared with the non-AAV population.
Plasma biomarkers outperform echocardiographic measurements for cardiovascular risk prediction in kidney transplant recipients: results of the HOME ALONE study
Insa E Emrich, Anja L Scheuer, Kyrill S Rogacev, Felix Mahfoud, Stefan Wagenpfeil, Danilo Fliser, Stephan H Schirmer, Michael Böhm, Gunnar H Heine
doi : 10.1093/ckj/sfab216
Clinical Kidney Journal, Volume 15, Issue 4, April 2022, Pages 693–702
Since kidney transplant recipients (KTRs) have a high cardiovascular disease burden, adequate risk prediction is of importance. Whether echocardiographic parameters and plasma biomarkers, natriuretic peptides [N-terminal pro-B-type natriuretic peptide (NT-proBNP)] and troponin T provide complementary or overlapping prognostic information on cardiovascular events remains uncertain.
Changing trends in presentation and indications of biopsy in lupus nephritis: data from the Spanish Registry of Glomerulonephritis
Amir Shabaka, Eugenia Landaluce-Triska, José Emilio Sánchez-�lvarez, Gema Fernández-Juárez
doi : 10.1093/ckj/sfab236
Clinical Kidney Journal, Volume 15, Issue 4, April 2022, Pages 703–708
With the ageing population and changes in the indications of diagnostic and protocol biopsies in systemic lupus erythematosus in recent years, an impact on the incidence and presentation of lupus nephritis (LN) is expected. The aim of this study was to analyse the epidemiological changes regarding clinical and histological presentation of LN in kidney biopsies performed from 1994 to 2019 included in the Spanish Registry of Glomerulonephritis.
Plasma copeptin is increased and associated with smaller kidney volume in young adults born very preterm
Adrien Flahault, Guillaume Bollée, Ramy El-Jalbout, Anik Cloutier, Robson A S Santos, Anne-Laure Lapeyraque, Thuy Mai Luu, Anne Monique Nuyt
doi : 10.1093/ckj/sfab226
Clinical Kidney Journal, Volume 15, Issue 4, April 2022, Pages 709–717
Plasma copeptin, a surrogate marker for vasopressin levels, is increased in neonates born preterm, particularly in those with a more severe neonatal course, as reflected by bronchopulmonary dysplasia. Copeptin levels in adulthood are unknown.
Sugar-sweetened beverage consumption and mortality of chronic kidney disease: results from the US National Health and Nutrition Examination Survey, 1999–2014
Xiao-Yu Cai, Nan-Hui Zhang, Yi-Chun Cheng, Shu-Wang Ge, Gang Xu
doi : 10.1093/ckj/sfab227
Clinical Kidney Journal, Volume 15, Issue 4, April 2022, Pages 718–726
The relationship between intake of sugar-sweetened beverages (SSBs) and the risk of death in patients with chronic kidney disease (CKD) is unclear. We evaluated the association between SSB intake and subsequent overall mortality in CKD patients.
How common is hyperkalaemia? A systematic review and meta-analysis of the prevalence and incidence of hyperkalaemia reported in observational studies
Toby Humphrey, Mogamat Razeen Davids, Mogamat-Yazied Chothia, Roberto Pecoits-Filho, Carol Pollock, Glen James
doi : 10.1093/ckj/sfab243
Clinical Kidney Journal, Volume 15, Issue 4, April 2022, Pages 727–737
The prevalence and incidence of hyperkalaemia, a potassium abnormality that can potentially have life-threatening consequences, are unclear.
Investigating the global prevalence and consequences of undiagnosed stage 3 chronic kidney disease: methods and rationale for the REVEAL-CKD study
Pamela Kushner, Emily Peach, Eric Wittbrodt, Salvatore Barone, Hungta Chen, Juan Jose Garcia Sanchez, Krister Järbrink, Matthew Arnold, Navdeep Tangri
doi : 10.1093/ckj/sfab235
Clinical Kidney Journal, Volume 15, Issue 4, April 2022, Pages 738–746
Timely diagnosis and treatment of stage 3 chronic kidney disease (CKD) can prevent further loss of kidney function and progression to kidney failure. However, contemporary data on the global prevalence of undiagnosed stage 3 CKD are scarce. REVEAL-CKD is a multinational, multifocal and observational study aiming to provide insights into undiagnosed stage 3 CKD in a large population.
Prevalence and outcomes of chronic liver disease in patients receiving dialysis: systematic review and meta-analysis
Oscar Swift, Shivani Sharma, Sivaramakrishnan Ramanarayanan, Hamza Umar, Keith R Laws, Enric Vilar, Ken Farrington
doi : 10.1093/ckj/sfab230
Clinical Kidney Journal, Volume 15, Issue 4, April 2022, Pages 747–757
Patients receiving dialysis for end-stage kidney disease (ESKD) commonly co-exhibit risk factors for hepatic impairment. This systematic review and meta-analysis aimed to quantify the coexistence of chronic liver disease (CLD) and characterize risk factors and outcomes.
Serum potassium variability as a predictor of clinical outcomes in patients with cardiorenal disease or diabetes: a retrospective UK database study
Glen James, Jennifer Kim, Carl Mellström, Kerrie L Ford, Nia C Jenkins, Carmen Tsang, Marc Evans, Phil McEwan
doi : 10.1093/ckj/sfab225
Clinical Kidney Journal, Volume 15, Issue 4, April 2022, Pages 758–770
Hyperkalaemia is an electrolyte abnormality associated with adverse clinical outcomes; however, few studies have investigated the relationship with patterns of hyperkalaemia over time. This study explored the impact of time spent in a hyperkalaemic state and variability of serum potassium (sK+) on major adverse cardiovascular events (MACE) and all-cause mortality in patients with chronic kidney disease (CKD), resistant hypertension, heart failure and diabetes.
Corticosteroids and mycophenolic acid analogues in immunoglobulin A nephropathy with progressive decline in kidney function
Ana Huerta, Eva Mérida, Laura Medina, Maria Fernandez, Eduardo Gutierrez, Eduardo Hernandez, Paula López-Sánchez, Angel Sevillano, Jose Portolés, Hernan Trimarchi, Manuel Praga
doi : 10.1093/ckj/sfab244
Clinical Kidney Journal, Volume 15, Issue 4, April 2022, Pages 771–777
A randomized controlled trial demonstrated a beneficial effect of corticosteroids (CS)Â +Â cyclophosphamide followed by azathioprine in progressive immunoglobulin A nephropathy (IgAN). Although treatment with CS and mycophenolic acid analogues (MPAAs) remains controversial in IgAN, there is no information about their effects in progressive IgAN.
Chronic prescription of antidepressant medication in patients with chronic kidney disease with and without kidney replacement therapy compared with matched controls in the Dutch general population
Manon J M van Oosten, Dan Koning, Susan J J Logtenberg, Martijn J H Leegte, Henk J G Bilo, Marc H Hemmelder, Kitty J Jager, Vianda S Stel
doi : 10.1093/ckj/sfab242
Clinical Kidney Journal, Volume 15, Issue 4, April 2022, Pages 778–785
Chronic kidney disease (CKD) is associated with a higher prevalence of depression, neuropathic pain and insomnia. These conditions are often treated pharmaceutically. In this study we aimed to determine the prevalence of chronic antidepressant use among CKD patients with and without kidney replacement therapy (KRT).
Associations between depressive symptoms and disease progression in older patients with chronic kidney disease: results of the EQUAL study
Boukje C Eveleens Maarse, Nicholas C Chesnaye, Robbert Schouten, Wieneke M Michels, Willem Jan W Bos, Maciej Szymczak, Magdalena Krajewska, Marie Evans, Olof Heimburger, Fergus J Caskey, Christoph Wanner, Kitty J Jager, Friedo W Dekker, Yvette Meuleman, EQUAL Study Investigators
doi : 10.1093/ckj/sfab261
Clinical Kidney Journal, Volume 15, Issue 4, April 2022, Pages 786–797
Depressive symptoms are associated with adverse clinical outcomes in patients with end-stage kidney disease; however, few small studies have examined this association in patients with earlier phases of chronic kidney disease (CKD). We studied associations between baseline depressive symptoms and clinical outcomes in older patients with advanced CKD and examined whether these associations differed depending on sex.
The relationship between uremic toxins and symptoms in older men and women with advanced chronic kidney disease
Ziad A Massy, Nicholas C Chesnaye, Islam Amine Larabi, Friedo W Dekker, Marie Evans, Fergus J Caskey, Claudia Torino, Gaetana Porto, Maciej Szymczak, Christiane Drechsler, Christoph Wanner, Kitty J Jager, Jean Claude Alvarez, EQUAL study investigators
doi : 10.1093/ckj/sfab262
Clinical Kidney Journal, Volume 15, Issue 4, April 2022, Pages 798–807
Patients with stage 4/5 chronic kidney disease (CKD) suffer from various symptoms. The retention of uremic solutes is thought to be associated with those symptoms. However, there are relatively few rigorous studies on the potential links between uremic toxins and symptoms in patients with CKD.
Native BK virus nephropathy in lung transplant: a case report and literature review
Waseem Albasha, Golnaz Vahdani, Ankita Ashoka, Erika Bracamonte, Amy A Yau
doi : 10.1093/ckj/sfab251
Clinical Kidney Journal, Volume 15, Issue 4, April 2022, Pages 808–811
Classically described in renal allografts, BK virus nephropathy is increasingly recognized in native kidneys of other non-renal solid organ transplants. We discuss a 68-year-old woman with a history of bilateral lung transplant referred for worsening renal function, confirmed to have BK virus nephropathy by biopsy with a serum BK virus polymerase chain reaction of over 59 million copies/mL. She was managed with a reduction in immunosuppression and intravenous cidofovir with no improvement in her clinical parameters. The seven prior reported cases of polyoma virus nephropathy in lung transplant recipients are reviewed, and the challenges of screening and management are discussed.
Genetic evaluation of paediatric nephrocalcinosis: phenotype-driven genetic panels reveal a rare diagnosis
Jenny Patterson, Zoe Jacob, Ben C Reynolds
doi : 10.1093/ckj/sfab279
Clinical Kidney Journal, Volume 15, Issue 4, April 2022, Pages 812–815
Monogenic causes of paediatric nephrocalcinosis are associated with extensive phenotypic variability. We report a 14-year-old male who presented at 8 years of age with incidentally identified nephrocalcinosis alongside growth impairment and dental anomalies. Extensive genetic investigation confirmed a molecular diagnosis of Bartter syndrome type II. This is exceptional in both late presentation and the presence of amelogenesis imperfecta, a very rare association of inherited tubulopathies. Details of the nephrocalcinosis gene panel analysed and associated phenotypes are presented to highlight the utility of a phenotype-driven genetic panel in resolving an atypical presentation of nephrocalcinosis, allowing precise diagnosis, tailored therapy and prognostication.
Immunogenicity, reactogenicity and breakthrough infections after two doses of the inactivated CoronaVac vaccine among patients on dialysis: phase 4 study
José Medina-Pestana, Cinthia Montenegro Teixeira, Laila Almeida Viana, Silvia Regina Manfredi, Monica Rika Nakamura, Elizabeth França Lucena, Adriano Luiz Amiratti, Helio Tedesco-Silva, Dimas Tadeu Covas, Marina Pontello Cristelli
doi : 10.1093/ckj/sfab258
Clinical Kidney Journal, Volume 15, Issue 4, April 2022, Pages 816–817
Antibody maintenance and breakthrough infections 6 months after complete COVID-19 vaccination with the mRNA-1273 and BNT162b2 vaccines in hemodialysis patients
Diana RodrÃguez-Espinosa, José Jesús Broseta, José Luis Bedini, Néstor RodrÃguez, Francisco Maduell
doi : 10.1093/ckj/sfab282
Clinical Kidney Journal, Volume 15, Issue 4, April 2022, Pages 818–819
Humoral and T-cell response to SARS-CoV-2 mRNA BNT162b2 vaccination in a cohort of kidney transplant recipients and their cohabitant living kidney donor partners
Vincenzo La Milia, Silvia Tonolo, Francesco Luzzaro, Claudio Bonato, Donatella Casartelli, Monica Limardo, Selena Longhi, Chiara Ravasi, Sara Viganò, Andrea Cavalli
doi : 10.1093/ckj/sfac010
Clinical Kidney Journal, Volume 15, Issue 4, April 2022, Pages 820–821
Influence of race in the estimation of glomerular filtration rate in patients with a high cardiovascular and renal risk
João Pedro Ferreira, Faiez Zannad, Scott D Solomon, Bertram Pitt, Patrick Rossignol
doi : 10.1093/ckj/sfab246
Clinical Kidney Journal, Volume 15, Issue 4, April 2022, Pages 822–824
Neutrophil gelatinase-associated lipocalin dipstick test in peritoneal dialysis patients with peritonitis
Sabrina Milan Manani, Grazia Maria Virzì, Matteo Marcello, Monica Zanella
doi : 10.1093/ckj/sfab249
Clinical Kidney Journal, Volume 15, Issue 4, April 2022, Pages 825–826
Raynaud's phenomenon triggered by the vasopressin V2 receptor antagonist tolvaptan in a patient with autosomal dominant polycystic kidney disease and Sjögren's syndrome
F J Roca Oporto, Jose L Rocha
doi : 10.1093/ckj/sfab260
Clinical Kidney Journal, Volume 15, Issue 4, April 2022, Pages 827–828
Deep learning to classify arteriovenous access aneurysms in hemodialysis patients
Hanjie Zhang, Dean Preddie, Warren Krackov, Murat Sor, Peter Waguespack, Zuwen Kuang, Xiaoling Ye, Peter Kotanko
doi : 10.1093/ckj/sfab278
Clinical Kidney Journal, Volume 15, Issue 4, April 2022, Pages 829–830
Weaning from concentrated ascites reinfusion therapy for refractory ascites by SGLT2 inhibitor
Yasunori Miyamoto, Akira Honda, Seiji Yokose, Mariko Nagata, Jiro Miyamoto
doi : 10.1093/ckj/sfab266
Clinical Kidney Journal, Volume 15, Issue 4, April 2022, Pages 831–833
Utility of semi-private messaging application (WhatsApp®) for Onconephrology education: a qualitative analysis of a ‘mastermind’ chat
Simoni Khashu, Nitya Wanchoo, Kayla D Finuf, Sebastian Lapman, Prakash Gudsoorkar, Kenar D Jhaveri
doi : 10.1093/ckj/sfab281
Clinical Kidney Journal, Volume 15, Issue 4, April 2022, Pages 834–838
Erratum to: Relapsing Minimal Change Disease Superimposed on Late-Onset p.N215S Fabry Nephropathy
Fabio R Salerno, Letizia Roggero, Federica Rossi, Agnese Binaggia, Silvio Bertoli, Federico Pieruzzi
doi : 10.1093/ckj/sfab191
Clinical Kidney Journal, Volume 15, Issue 4, April 2022, Page 839
